Search clinical trials for: Placebo Liraglutide Pen Injector

Total 2175 results

Canadian Medical and Surgical Knowledge Translation...
Unity Health Toronto; Western University, Canada

Recruiting

Semaglutide and Vascular Regeneration (SEMA-VR)

Cardiovascular Diseases | Obesity | Diabetes Mellitus, Type 2 | Atherosclerosis

Canada
University of Oulu
Turku University Hospital; Oulu University Hospital; Tampere University Hospital and other collaborators

Completed

Incretin-based Therapy in Early Diagnosed Type 1 Diabetes

Type 1 Diabetes

Finland, Sweden
Novo Nordisk A/S

Completed

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Italy, Poland, Russian Federation, United Kingdom, Canada, Denmark, Sweden, Austria, Belgium, Spain, Ireland, Norway, Serbia, Finland, Portugal, Ukraine
Tulane University School of Medicine
Novo Nordisk A/S

Completed

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

Hypertensive Disease | Diabetes Mellitus, Non-Insulin-Dependent

United States
Novo Nordisk A/S

Completed

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin (SCALE™ Insulin)

Obesity | Metabolism and Nutrition Disorder

United States, Israel, Italy, Mexico, Canada, Germany, Turkey
Novo Nordisk A/S

Completed

The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Mayo Clinic
Novo Nordisk A/S

Active, not recruiting

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

Obesity

United States
Aga Khan University
Rehman Medical Institute - RMI

Recruiting

"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

Diabetes Mellitus, Type 2 | Weight Change, Body

Pakistan
Novo Nordisk A/S

Completed

A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

Diabetes Mellitus, Type 2 | Diabetes

India, Italy, Spain, Austria, Finland, Hungary, Turkey, France, United Kingdom, Switzerland, Bulgaria, Germany, South Africa, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Italy, United Kingdom, France, Serbia, Germany, South Africa, Canada, Ukraine, United Arab Emirates
Novo Nordisk A/S

Completed

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Diabetes Mellitus, Type 2 | Diabetes

United States
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-M)

Diabetes Mellitus, Type 2

United States, Canada, Romania, Russian Federation, Ukraine, Germany, Spain, Philippines, Czech Republic, Mexico, Croatia, Chile, Morocco, South Africa, Australia, Venezuela
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (Ellipse™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Russian Federation, Spain, United Kingdom, Austria, Belgium, Mexico, Sweden, Israel, Taiwan, Hungary, Malaysia, Serbia, Turkey, Denmark, Greece, Thailand, North Macedonia, Norway, Portugal, Germany, Romania and more
Novo Nordisk A/S

Completed

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers

Diabetes Mellitus, Type 2 | Diabetes

Japan
University of Aarhus
Novo Nordisk A/S; University of Copenhagen

Completed

Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Denmark
Novo Nordisk A/S

Completed

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Jens Faber

Completed

LIPT - Liraglutide in Polycystic Ovary Syndrome (LIPT)

Cardiovascular Disease | Polycystic Ovary Syndrome

Denmark
Stanford University

Completed

Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

Older Adults | Pre-diabetes
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Healthy Male Volunteers

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting (SCALE™ IBT)

Obesity | Metabolism and Nutrition Disorder

United States
Tina Vilsboll

Completed

The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes

Type 2 Diabetes

Denmark
Aalborg University Hospital
Novo Nordisk A/S

Completed

Treatment of Diabetic Neuropathy With Liraglutide (TODINELI)

Diabetes Mellitus, Type 1 | Type 1 Diabetes Mellitus

Denmark
Novo Nordisk A/S

Completed

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy (DUAL™IV)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Puerto Rico, Germany, Turkey, Canada, Bulgaria
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, India, Belgium, Mexico, Tunisia, Japan, Israel, Korea, Republic of
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (GETGOAL-S)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Germany, Netherlands, Turkey, Bulgaria, India, Taiwan, Czech Republic, Tunisia, Japan, Egypt, Israel, Korea, Republic of, Thailand
University of Birmingham
Novo Nordisk A/S; Wellcome Trust

Completed

Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis (LEAN)

Nonalcoholic Steatohepatitis

United Kingdom
Novo Nordisk A/S

Completed

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

Diabetes Mellitus, Type 2

Germany
Universitätsklinikum Hamburg-Eppendorf

Terminated

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

Obesity

Germany
Psychiatric Centre Rigshospitalet
University of Cambridge; University Hospital, Gentofte, Copenhagen

Unknown

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? (GREAT)

Impaired Glucose Tolerance Associated With Drugs

Denmark
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-F1)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Romania, Ukraine, Germany, Italy, Estonia, Malaysia, Philippines, Mexico, Lithuania, Colombia, Slovakia, Chile
Sanofi

Completed

Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (GetGoal-M-Asia)

Type 2 Diabetes Mellitus

China, Hong Kong, Malaysia, Thailand
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Non-small Cell Lung Cancer

China
Turku University Hospital

Active, not recruiting

Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes (Liragest)

Gestational Diabetes

Finland
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Novo...

Not yet recruiting

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Obesity | Diabetes type1

United States
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (GETGOAL-L)

Diabetes Mellitus, Type 2

United States, France, Canada, Brazil, Russian Federation, Germany, Italy, Turkey, India, Mexico, Egypt, United Kingdom, Korea, Republic of, Chile, Puerto Rico
Hospices Civils de Lyon
GlaxoSmithKline

Recruiting

Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices (SECURE)

Asthma

France
University of Nottingham
Medical Research Council

Recruiting

Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets (SemVLCD)

Type 2 Diabetes Mellitus in Obese

United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (GETGOAL-P)

Diabetes Mellitus Type 2

United States, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico, Romania, Turkey
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) (GETGOAL-L-ASIA)

Diabetes Mellitus, Type 2

Philippines, Taiwan, Japan, Korea, Republic of
Universitaire Ziekenhuizen KU Leuven

Unknown

The Effect of Liraglutide on the GIT (LIRHV)

Obesity
Annesofie Faurschou
University of Copenhagen

Completed

The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis

Psoriasis

Denmark
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO)

Diabetes Mellitus, Type 1

United States
Postgraduate Institute of Medical Education and...

Completed

Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients

Weight Loss

Search clinical trials for: Placebo Liraglutide Pen Injector

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations